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ABSTRACT 
 The study represents the first report on the development of spectrophotometric methods for determination of 
ethamsylate (EST) in the presence of hydroquinone as an impurity and/or acidic degradation product. The proposed me-
thods are based on the reaction of EST through it,s secondary amino group either with 1,2-naphthoquinone-4-sulphonate 
sodium (NQS) at pH 10.7 or 2,4-dinitrofluorobenzene (DNFB) at pH 9.3 to form orange and yellow colored reaction prod-
ucts peaking at 478 and 387 nm for methods (I) and (II), respectively. The different experimental parameters affecting the 
development and stability of the reaction products in methods (I) and (II) were carefully studied and optimized. The absor-
bance-concentration plots were rectilinear over the concentration ranges of 2-30 and 2-14 µg mL−1 for methods (I) and 
(II), respectively. The lower detection limits were 0.13 and 0.19 µg mL−1 and the lower quantitation limits were 0.44 and 
0.63 µg mL−1 for methods (I) and (II), respectively. Both methods were successfully applied to commercial ampoules and 
tablets. 
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1. Introduction:  
 Ethamsylate (EST); is N-ethylethanamine 2,5-dihydroxybenzenesulphonate (Fig. 1). It is a haemostatic agent 
that appears to maintain the stability of capillary walls and correct abnormal platelets adhesion. It is given for prophylaxis 
and control of hemorrhages from small blood vessels [1]. The British Pharmacopoeia [2] recommended potentiometric 
titration method for the determination of EST raw material, using cerium (IV) sulphate as a titrant and a TLC method for 
detection of it,s known impurity, hydroquinone (HQ) (Fig. 1). In addition, the acid degradation product of EST was reported 
to be HQ by Kaul et al [3].  
 Several analytical methods were developed for the assay of ethamsylate. These methods include; spectrophotometry [4-
8], spectrofluorimetry [9], HPTLC [10], HPLC [3, 11], electrochemical methods [12-15], chemiluminescence [16-19] and 
capillary electrophoresis [20]. 
 A survey of the literature reveals that, the reported spectrophotometric methods show either low sensitivity or unsuitable 
linearity range and need tedious extraction procedures [4] and/or suffer from interference due to measurement of absor-
bance in the near UV region [5]. In addition, no spectrophotometric method has been developed for determination of EST 
in presence of its degradation product (HQ). Therefore, our target was to develop stability-indicating methods for the anal-
ysis of EST in pharmaceutical formulations.  
 1,2-Naphthoquinone-4-sulphonate sodium and 2,4-Dinitrofluorobenzene have been used as chromogenic reagents for the 
analysis of many pharmaceuticals [21-25]. 
2. Experimental: 
2.1. Instruments: 
 A Shimadzu UV-Visible 1601 PC Spectrophotometer (Kyoto, Japan) was used for spectrophotometric measure-
ments (P/N 206-67001). The recording range was 0-1.0. 
 A Consort NV P901 digital pH Meter (Belgium) calibrated with standard buffers was used for checking the pH of the 
buffer solutions. 
2.2. Reagents and materials:  
 All the reagents used were of Analytical Reagent grade and distilled water was used throughout the work. 
 Ethamsylate (Memphis Chemical CO, Cairo, Egypt). 
 Pharmaceutical preparations containing EST were obtained from commercial sources in the local market: 
 Dicynone® ampoules; batch # CDE0953, labeled to contain 250 mg EST/2 mL. 
 Dicynone® tablets; batch # 312265, labeled to contain 250 mg EST/tablet. 
 Dicynone® 500 tablets; batch # CDE0876, labeled to contain 500 mg EST/tablet. 
 Dicynone® ampoules, Dicynone® 500 tablets (Minapharm, Egypt) and Dicynone® tablets (Memphis Co. for Phar-
ma. & Chemical Ind., Cairo, Egypt) are manufactured under license of OM PHARMA (Meyrin, Geneva, Switzer-
land). 
 Hydroquinone (El-Nasr Pharmaceutical Chemicals Company (ADWIC), Abu Zaabal, Egypt). 
 1,2-Naphthoquinone-4-sulphonate sodium (Fluka Chemie, Germany) solution was freshly prepared as 0.5% (w/v) 
aqueous solution. 
 2,4-Dinitrofluorobenzene (Fluka Chemie, Germany) solution was freshly prepared as 0.3% (v/v) in methanol.  
 Methanol, hydrochloric acid, sodium hydroxide and boric acid (BDH, UK). 
 Borate buffer solutions (0.2 M) were prepared by mixing appropriate volumes of 0. 2 M boric acid with 0.2 M sodium 
hydroxide and adjusting the pH to 10.7 or 9.3 using pH Meter. 
2.3. Standard solutions:  
 Stock solution of EST was prepared by dissolving 10.0 mg of the drug in 100 mL of distilled water or methanol 
for method I or II, respectively. This solution was further diluted with the same solvent as appropriate to obtain the working 
concentration range. The stock solution is stable for 7 days when kept in the refrigerator.  
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2.4. General recommended procedures: 
2.4.1. Procedures for calibration graphs: 
2.4.1.i. Method I: 
 To a set of 10 mL volumetric flasks, appropriate aliquots of the standard working solution were quantitavely 
transferred, to obtain final concentrations in the range of 2-30 µg mL-1. To each flask, 1mL of borate buffer solution (pH 
10.7) followed by 1 ± 0.2 mL of NQS solution (0.5%) were added and mixed well. The solutions were heated in thermostat-
ically controlled water bath at 60 ± 5˚C for 15 min. The reaction was stopped by cooling under tap water, and solutions 
were completed to the volume with distilled water. The absorbance of the resulting solutions was measured at 478 nm 
against a reagent blank prepared simultaneously. The calibration graph was constructed by plotting the absorbance ver-
sus the final concentration of the drug. Alternatively, the corresponding regression equation was derived. 
2.4.1.ii. Method II: 
 To a set of 10 mL volumetric flasks, appropriate aliquots of the standard working solution were quantitavely 
transferred, to obtain final concentrations in the range of 2-14 µg mL-1. To each flask, 0.8 mL of borate buffer solution (pH 
9.3) followed by 2.6 ± 0.2 mL of DNFB solution (0.3% v/v) were added and mixed well. The solutions were heated in ther-
mostatically controlled water bath at 75 ± 5˚C for 20 min.  
 The reaction was stopped by cooling under tap water, and then 0.2 mL of conc HCl was added and the solutions 
were made up to volume with methanol. The absorbance was measured at 387 nm against a reagent blank.  
 The absorbance was plotted versus the final concentration of the drug to obtain the calibration graph. Alterna-
tively, the corresponding regression equation was derived. 
2.4.2. Assay procedure for analysis of EST/HQ synthetic mixtures: 
 Aliquots of EST and HQ standard solutions in different ratios were transferred into a series of 10 mL vo-
lumetric flasks. The procedures described under "Calibration Graphs" were then performed for both methods. The percen-
tage recoveries were calculated by referring to the calibration graphs, or using the corresponding regression equations. 
2.4.3. Assay procedure for dosage forms: 
(a) Procedure for tablets: 
 Ten tablets (Dicynone® 250 mg or 500 mg) were accurately weighed, finely pulverized, and thoroughly mixed. 
An accurately weighed amount of powdered tablets equivalent to 10.0 mg of EST was transferred into small conical flask 
and extracted with 3 x 30 mL of distilled water for method I or methanol for method II. The extract was filtered into 100 mL 
volumetric flask. The conical flask was washed with few mLs of distilled water or methanol. The washings were passed 
into the same volumetric flask and completed to the volume with the same solvent. Aliquots of these solutions were trans-
ferred into a series of 10 mL volumetric flasks and the procedures described under " Calibration Graphs" were then per-
formed for both methods. The nominal content of the tablets was determined either from the previously plotted calibration 
graphs or using the corresponding regression equations.  
 (b) Procedure for ampoules: 
 The contents of five ampoules (Dicynone®) were mixed well. An aliquot of the solution equivalent to 125.0 mg 
EST was transferred into 25 mL volumetric flask. The solution was diluted to the mark with distilled water or methanol for 
method I or II, respectively. 
Then, 4 mL were transferred into 100 mL volumetric flask. Aliquots of these solutions were quantitavely trans-
ferred into a series of 10 mL volumetric flasks and the procedures described under "Calibration Graphs" were then applied 
for both methods. The nominal content of the ampoules was determined either from the previously plotted calibration 
graph or using the corresponding regression equation. 
 3. Results and Discussion: 
 The chemical structure of EST and HQ are closely related. Therefore, the determination of EST in presence of 
HQ is a challenging problem. However, the presence of secondary amino group in the chemical feature of EST only which 
is susceptible to derivatization with nucleophilic reagents such as NQS or DNFB, initiated the present study and allowed 
the determination of EST in presence of HQ without any interference. 
 Ethamsylate was found to react with NQS in borate buffer of pH 10.7 yielding a highly colored orange reaction 
product with maximum absorbance at 478 nm (Fig. 2). 
 Also, the drug was found to react with DNFB in borate buffer of pH 9.3 and a yellow colored reaction product 
with maximum absorbance at 387 nm was formed (Fig. 2). 
 
 
ISSN 2321-807X 
1226 | P a g e                                                       J a n u a r y  2 4 ,  2 0 1 4  
3.1. Study of experimental parameters:  
 The experimental conditions were optimized by varying each in turn while keeping all others constant. These va-
riables include; effect of pH and volume of buffer, effect of the concentration of reagents, effect of heating temperature and 
heating times, effect of diluting solvent and effect of time on stability of the reactions products. 
3.1.1. Effect of pH and volume of buffer: 
 According to the literature, the reaction of amines with NQS and DNFB was carried out in alkaline medium. 
 So, the influence of pH on the formation of the reactions products was studied over the range of 6.0-12.0 using 
0.2 M borate buffer solution. Maximum and constant absorbance intensities were achieved at pH 10.7 ± 0.5 for method I 
and 9.3 ± 0.2 for method II. Therefore, pH 10.7 and 9.3 were chosen as the optimum pH values for methods I and II, re-
spectively (Fig. 3). 
 Maximum absorbance intensities were achieved using 1.0 ± 0.2 mL or 0.8 ± 0.3 mL of borate buffer solutions for 
methods I and II, respectively (Fig. 4). So that, 1.0 mL of borate buffer solution of pH 10.7 and 0.8 mL of borate buffer so-
lution of pH 9.3 were chosen as the optimum buffer volumes for methods I and II, respectively. 
3.1.2. Effect of the concentration of reagents solutions: 
 The influence of the reagents concentrations was studied using different volumes of either 0.5% w/v solution of 
NQS (method I) or 0.3% v/v solution of DNFB (method II). It was found that, increasing volumes of the reagents produced 
a proportional increase in the absorbance values. Maximum and constant absorbance intensities were achieved using 
volumes of the reagents ranged from 0.8-1.2 or 2.4-2.8 mL of NQS or DNFB for method I or II, respectively. Further in-
crease of the reagents volumes produced gradual decrease in the absorbance intensities. Therefore, 1.0 ± 0.2 mL of 0.5% 
w/v NQS solution and 2.6 ± 0.2 mL of 0.3% v/v DNFB solution were chosen as the optimal volumes of the reagents for 
methods I and II, respectively (Fig. 5). In method II, addition of 0.2 mL of conc HCL is essential to remove excess DNFB 
reagent which interferes with the measurement of reaction product. Where, the excess DNFB is acid hydrolyzed to the 
colorless 2,4-dinitrophenol allowing the determination of EST-DNFB derivative which remains stable.  
3.1.3. Effect of temperature and heating time: 
 Preliminary studies showed that the reaction rates were very slow at room temperature in both methods. So, the 
reactions were performed in a thermostatically controlled water bath at different temperature settings ranging from (25–
100 °C) for various time intervals. For both methods, the results revealed that increasing the temperature resulted in an 
increase in the absorbance values of the reactions products. The maximum absorbance values were attained at 55-65 °C 
with in 15 min and 70-80 °C with in 20 min for methods I and II, respectively (Fig. 6, 7). At higher temperatures, the absor-
bance of the reaction product decreased gradually in case of method I, while precipitation in the method II was observed. 
The decrease in the absorbance was probably attributed to the instability of the EST derivatives at higher temperatures. 
Therefore, the studies were carried out at 60 and 75 °C for methods I and II, respectively. 
3.1.4. Effect of diluting solvent: 
 The effect of diluting solvent on the absorbance intensities of the reaction products was tested using different 
solvents viz water, methanol, ethanol, acetone, acetonitrile and dimethylformamide. Using water and methanol as diluting 
solvents gave the highest absorbance values and more reproducible results for methods I and II, respectively. So, they 
were selected as the best solvents.  
3.1.5. Effect of time on stability of the reactions products: 
 Regarding the stability of the produced derivatives, both were found to be stable at room temperature for approx-
imately 1 hour. 
3.2. Validation of the proposed methods: 
 The validity of the proposed methods was tested regarding linearity, specificity, accuracy, repeatability and in-
termediate precision according to ICH Q2(R1) recommendations [26]. 
3.2.1. Linearity: 
 The calibration graphs obtained by plotting the values of the absorbance versus the final concentrations of the 
drug (µg mL-1) were found to be rectilinear over the concentration ranges cited in Table 1.  
  The validity of the methods was proved by statistical evaluation of the regression data, regarding the 
standard deviation of the residuals (Sy/x), the standard deviation of the intercept (Sa) and standard deviation of the slope 
(Sb) (Table 1). The small values of the figures indicate low scattering of the points around the calibration line and high 
precision. 
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3.2.2. Limit of Quantitation and Limit of Detection:  
 Limit of Quantitation (LOQ) and Limit of Detection (LOD) were calculated according to ICH Q2(R1) recommenda-
tion using the following equations [26]: 
 LOQ = 10 Sa/b 
 LOD = 3.3 Sa/b 
 Where Sa is the standard deviation of the intercept of regression line, and b is the slope of the regression line. 
The values of LOD and LOQ for both methods are abridged in Table 1. 
3.2.3. Accuracy:  
 To test the validity of the proposed methods, they were applied to the determination of pure sample of EST over 
the concentration ranges cited in Table 1. The results obtained were in good agreement with those obtained using the 
comparison method [6]. Statistical analysis of the result obtained using Student t-test and the variance ratio F-test [27] 
revealed no significance differences between the proposed and comparison methods regarding the accuracy and preci-
sion, respectively (Table 2). The comparison method is based on reaction of EST with 3-methyl-2-benzothiazolinone hy-
drazone hydrochloride in presence of cerium (IV) ammonium sulfate at room temperature for 20 min and measuring and 
the absorbance of the reaction product at 514 nm [6]. 
3.2.4. Precision:  
3.2.4.i. Repeatability (intra-day):  
 The repeatability was performed over the specific concentration ranges through replicate analysis of three con-
centrations of EST in pure form on three successive occasions.The results are presented in Table 3.  
3.2.4.ii. Intermediate precision (inter-day): 
 Intermediate precision was tested by repeated analysis of EST in pure form using the concentrations shown in 
Table 3 for a period of 3 successive days.  
 High % recovery and low % RSD indicate high accuracy and precision of theproposed methods, respectively 
(Table 3).  
3.2.5. Robustness:  
 The robustness of the procedures adopted in the two proposed methods was demonstrated by the constancy of 
the absorbance intensity with the deliberated minor changes in the experimental parameters.  
 For method I, the changes included the pH of borate buffer solution, 10.7 ± 0.5, the change in the volume of the 
buffer solution, 1.0 ± 0.2 mL, the change in the volume of NQS (0.5% w/v), 1.0 ± 0.2, the change in the heating tempera-
ture, 60 ± 5˚C and the change in the heating time, 15 ± 5 min.  
 Meanwhile, for method II these changes included the pH of borate buffer solution, 9.3 ± 0.2, the change in the 
volume of the buffer solution, 0.8 ± 0.3 mL, the change in the volume of DNFB (0.3% v/v), 2.6 ± 0.2 mL, the change in the 
heating temperature, 75 ± 5˚C and the change in the heating time, 20 ± 5 min. These minor changes that may take place 
during the experimental operation didn’t affect the absorbance of the reaction products. 
3.4.6. Selectivity: 
 The selectivity of the methods was investigated by observing any interference encountered from the common 
tablets excipients and ampoules. It was found that, these excipients didn,t interfere with the results of the proposed me-
thods (Table 4). 
3.3. Analysis of EST/HQ synthetic mixtures:   
 Methods I and II were applied to the simultaneous determination of EST and HQ in synthetic mixtures containing 
different ratios of both compounds. The concentrations of both compounds in the synthetic mixture were calculated ac-
cording to the linear regression equations. The results indicate the accuracy of the proposed methods as shown in Table 
5. 
3.4. Pharmaceutical Applications: 
 The proposed methods were successfully applied to the determination of the studied drug in its pharmaceutical 
preparations. The results obtained were statistically compared to those of the comparison method [6] using Student's t-test 
for accuracy and the variance ratio F-test for precision, respectively (Table 4). The results obtained indicate no significant 
difference between the proposed methods and the comparison one. 
3.5. Molar ratio and mechanism of the reaction: 
 The stoichiometry of the reactions in the two methods was studied adopting the limiting logarithmic method [28]. 
Plots of log absorbance versus log [reagent] and log [drug] gave straight lines. The slopes of which were 1.1 and 0.8 for 
NQS and EST in method I, respectively (Fig. 8). While, the slopes were 0.7 and 0.9 for DNFB and EST in method II, re-
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spectively (Fig. 8). Hence, It is concluded that the reactions proceed in the ratio of 1:1, confirming that one molecule of the 
drug condenses with one molecule of NQS or DNFB in method I or II, respectively.  
 Based on the absorbed molar ratio, proposed reaction pathway are given in sheme 1 and 2. 
4. Conclusion 
 The present study described for the first time, a successful analysis of EST in the presence of it,s acidic degra-
dation product Hydroquinone with simple spectrophotometric methods. These methods could be used for determination of 
EST in pure form and pharmaceutical dosage forms. They were found to be sensitive, accurate and don,t need expensive 
sophisticated instrument. Moreover, the reproducibility as well as convenience makes the two proposed methods suitable 
for routine analysis in quality control laboratories.  
 
Table (1): Analytical performance data for the proposed methods. 
 
Parameter 
 
Method I 
 
 
Method II 
Linearity range (µg/mL)                   2.0 - 30.0             2.0 - 14.0 
Intercept (a)                                         4.47 x 10
-3
 3.93 x 10
-3
 
Slope (b)                  2.38 x 10
-2
 5.77 x 10
-2
 
Correlation coefficient (r)                    0.9999             0.9999 
S.D. of residuals (Sy/x) 2.27 x 10
-3
   4.73 x 10
-3
 
S.D. of intercept (Sa)                  1.04 x 10
-3
            3.62 x 10
-3
 
S.D. of slope (Sb)                   9.5 x10
-5
            4.57 x10
-7
 
Percentage relative standard dev-
iation, % RSD 
                    1.23                    0.69                         1.27 
Percentage relative error, % Error                     0.50               0.52 
Limit of detection, LOD (µg/mL)                     0.13               0.19 
Limit of quantitation, LOQ (µg/mL)                        0.44                 0.63 
Molar absorptivity, ε (L/mol./cm.) 6250 15349 
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Table (2): Application of the proposed and comparison methods to the determination of ethamsylate in pure form. 
 
 
Parame-
ter   
 
Method I   Method II  
Comparison  
 method [6] 
 
 Conc. tak-
en 
 (µg mL-1) 
Conc. 
found  
(µg mL-1) 
% 
Found * 
Conc. tak-
en 
 (µg mL-1) 
Conc. 
found  
(µg mL-1) 
% 
Found 
* 
% Found 
       
   2.00 
 
1.968 
   
98.38 
  
  2.00 
   
 2.045 
  
102.25 
    
97.30 
     4.00 3.938  98.45     4.00    4.032 100.81  102.15 
     8.00 8.123  101.54     8.00    7.890   98.63   98.80 
    10.00 10.040  100.47    10.00    9.921   99.21  
    20.00 19.888  99.44    12.00    12.010 100.08 
    30.00 30.039  100.13    14.00    14.070 100.50 
x   ± 
S.D. 
99.74 ±1.23 100.25 ± 1.27 
99.45 ± 2.36 
T 0.20 0.69  
F 
 
3.67 3.42  
 
 * Each result is the average of three seperate determinations. 
 - The tabulated t and F values are 3.36 and 5.79 at p = 0.05, respectively [28]. 
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Table (3): Precision data for the determination of EST by the propose methods. 
Amount taken 
(g/mL) 
 
% Found 
 
% RSD 
` 
% Error 
 Method I 
 
   
Intraday    
8.0 98.91  ± 0.51                0.52 0.30 
               10.0   99.61  ±  0.68               0.68 0.39 
20.0            99.09  ±  1.87              1.89 1.09 
Interday  
 
  
8.0 99.38 ± 0.88              0.89            0.51 
 10.0 102.03 ± 0.05              0.05            0.03 
20.0 100.47 ± 2.33              2.32           1.34 
    Method II    
    
Intraday  
 
  
8.0 99.41 ± 0.70            0.70            0.40 
10.0             99.38 ± 0.84            0.85            0.49 
12.0 99.44  ± 1.93            1.94            1.12 
Interday    
8.0            99.48  ± 0.32          1.33 0.77 
10.0 100.15  ± 1.32         1.32  0.76 
    12.0 100.6  ± 0.57         0.57 0.33 
 
 N. B. Each result is the average of three separate determinations. 
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Table (4): Assay results for the determination of EST in dosage forms by the proposed and comparison methods. 
Pharma-
ceutical 
preparation 
                         Method I Method II  Comparison 
method [6] 
   Conc. 
  taken  
(µg mL1) 
Conc. 
 found  
(µg mL-1) 
% Found    Conc.  
taken   
(µg mL-1) 
Conc. 
 found  
(µg mL-1) 
 
% Found 
% Found 
1- Dicy-
none® 
ampoules 
 
    10.00             10.00            9.990              99.90     4.00    4.039   100.98 100.00 
(250 mg
EST/2 mL) 
    20.00                   19.607                    98.04                      8.00    7.904    98.80 98.33 
 25.00   24.965  99.86   10.00     9.901    99.01 98.98 
 30.00   29.601  98.67   12.00   12.120                       101.00  
Mean ± 
S.D. 
             99.12  ±  0.92                     99.95 ± 1.21  
 
  99.10 ± 0.84         
t                       0.03                         1.03   
F              1.20 (19.16)                     2.06 (19.16) 
 
    
Nominal 
content of 
Ampoules. 
                247.80                        249.88  
2- Dicy-
none® 
tablets 
10.00  10.001 100.91    4.00       4.000     100.00         99.86 
(250 mg 
EST/tablet) 
20.00  19.602  98.01 8.00       7.849      98.11        101.99 
 25.00   25.401 101.61 10.00   9.991       99.91        101.02 
 30.00   29.706   99.02 12.00    12.120     101.00                                                      
 Mean  ±  
S.D 
                  99.89 ± 1.66 99.76 ±  1.20 100.96 ± 1.07 
 
 
 
 
 
 
 
t                     0.93                        1.36  
F             2.41 (19.60)                   1.26 (19.60) 
Nominal 
content of                           
tablet.                 
               249.73                      249.40 
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3- Dicy-
none® 500 
tablets 
 10.00     10.198     101.98 4.00 3.999 100.00       101.99 
(500 mg 
EST/tablet) 
20.00     19.602      98.01 8.00     7.999      98.64       100.00 
 25.00     24.941      99.76 10.00 9.664 96.64         98.98 
                      30.00      30.201      100.67                     12.00     11.791      98.26  
Mean ± 
S.D 
                 100.11 ± 1.67 98.39 ± 1.38  100.32 ± 1.53        
t                         0.17 *                           1.74  
F                 1.19 (19.16)                     1.23 (9.55) 
 
Nominal 
content of  
tablet.               
                
        
                    
                  500.55 
                      
                    491.95 
 
All the pharmaceutical preparations are manufactured under license of OM PHARMA, Switzerland. N.B.  Each result is the 
average of three separate determinations.   
 * The tabulated t value is 2.57 at  p = 0.05 [27]. 
 
Table (5): Application of the proposed methods for the determination of EST in presence of hydroquinone. 
 
 
Sample 
 
Conc. taken 
(µg mL-1) 
  
Conc. found 
(µg mL-1) 
 
% Found 
EST HQ  EST            EST 
EST and HQ  
synthetic mixture 
20.0 0.2  20.020 100.01 
  0.4 19.989 99.95 
  0.8 19.956 99.78 
  1.2 20.405 102.03 
  1.6 20.014 
 
100.07 
  2.0 19.876 99.38 
(x )    100.02 
± SD    0.93 
% RSD    0.93 
% Error    0.38 
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 10.0 0.1 9.990 99.90 
  0.2 10.089 100.89 
  0.4 9.958 99.58 
  0.6 9.907 99.07 
  0.8 10.057 100.57 
  1.0 10.023 100.23 
(x )    100.04 
± SD    0.67 
% RSD    0.67 
% Error    0.27 
 
 
 
 
 
 
 
 
 
  
Ethamsylate 
 
 
 
 
Hydroquinone 
 
Fig. (1): Structure formulae of the studied drugs. 
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Fig. (2): Absorption spectra of 
(A) reaction product of ethamsylate (30 µg mL-1) with NQS at pH 10.7. 
(B) reaction product of ethamsylate (14 µg mL-1) with DNFB at pH 9.3. 
 
 
 
Wavelength (nm) 
A
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Fig. (3): 
Effect of pH on the absorbance of the reactions products of 
Ethamsylate (30 µg mL-1) with NQS (method I). 
Ethamsylate (14 µg mL-1) with DNFB (method II). 
` 
Fig. (4): 
Effect of volume of 0.2 M borate buffer on the absorbance of the reactions products of 
Ethamsylate (30 µg mL-1) with NQS (method I).  
Ethamsylat (14 µg mL-1) with DNFB (method II). 
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Fig. (5): 
 Effect of volume of the reagents on the absorbance of the reactions products of 
Ethamsylate (30 µg mL-1) with NQS (method I).  
Ethamsylate (14 µg mL-1) with DNFB (method II). 
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Fig. (6): 
 Effect of heating temperature on the absorbance of the reactions products 
Ethamsylate (30 µg mL-1) with NQS for 15 min (method I).  
 Ethamsylate (14 µg mL-1) with DNFB for 20 min (method II ). 
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Fig. (7): 
Effect of heating time on the absorbance of the reactions products 
Ethamsylate (30 µg mL-1) with NQS (method I). 
Ethamsylate (14 µg mL-1) with DNFB (method II). 
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Fig. (8): 
Limiting logarithmic plots for the molar reactivity of EST with the reagents: 
(A) Log A vs Log [EST] when [reagent] is kept constant. 
(B) Log A vs Log [reagent] when [EST] is kept constant. 
 
 
 
Scheme 
1-Proposed reaction pathway between ethamsylate and 1, 2-Naphthoquinone-4-sulphonate sodium under the described 
reaction condition 
2- Proposed reaction pathway between ethamsylate and 2, 4-Dinitrofluorobenzene under the described reaction condition. 
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